All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
CoA Therapeutics represents the 19th subsidiary in three years for parent company Bridgebio Pharma Inc., adding a small-molecule approach to increase levels of coenzyme-A, or CoA – thus, the startup's intuitive name – in genetic disorders associated with CoA deficiency. Through its model of housing each therapeutic effort in an individual subsidiary supported by shared central resources, Bridgebio committed funds to drive CoA's lead program through human proof of concept.